GSK in talks to buy cancer biotech Nuvalent for more than $9bn
- Posted on June 9, 2026
- By Financial Times
- 0 Views
- 1 min read
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year
